Skip to main content
KalVista Pharmaceuticals, Inc logo
Menu toggle

Main navigation

  • About KalVista
    • Senior Management
    • Board of Directors
    • Contact Us
    • Careers
  • Products & Pipeline
    • Pipeline
    • KalVista for HAE
    • KVD900
    • KVD824
    • Factor XIIa
    • KalVista for DME
    • Publications
  • For Patients
    • HAE Resources
    • KVD900
    • KVD824
    • Factor XIIa
    • DME Resources
  • For Healthcare Providers
    • HAE Resources
    • KVD900
    • KVD824
    • Factor XIIa
    • DME Resources
    • Publications
    • Expanded Access
  • For Investors
    • Stock Information
    • News Releases
    • Events Calendar
    • Presentations
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance

KalVista Pharmaceuticals
creating a new generation of small molecule protease inhibitors for HAE and DME

Hereditary Angioedema (HAE)

Diabetic Macular Edema (DME)

News

Kalvista Pharmaceuticals

KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

Feb 18, 2021
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Feb 16, 2021
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock

Feb 10, 2021
All News
  • Print Page
  • Email Alerts
  • RSS
  • Search

Footer

  • About KalVista
  • Products & Pipeline
  • For Patients
  • For Healthcare Providers
  • For Investors
  • Contact Us
+1 (857) 999 0075 info@kalvista.com

Social Menu

  • Linked In
  • Twitter
Copyright © 2021 | All rights reserved.

Footer Bottom

  • KalVista Terms
  • Privacy